|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZDHHC20 |
Gene summary for ZDHHC20 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZDHHC20 | Gene ID | 253832 |
| Gene name | zinc finger DHHC-type palmitoyltransferase 20 | |
| Gene Alias | 4933421L13Rik | |
| Cytomap | 13q12.11 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | B4DRN8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 253832 | ZDHHC20 | CCI_2 | Human | Cervix | CC | 1.32e-06 | 9.42e-01 | 0.5249 |
| 253832 | ZDHHC20 | CCI_3 | Human | Cervix | CC | 1.75e-05 | 6.52e-01 | 0.516 |
| 253832 | ZDHHC20 | LZE4T | Human | Esophagus | ESCC | 2.27e-02 | 1.56e-01 | 0.0811 |
| 253832 | ZDHHC20 | LZE20T | Human | Esophagus | ESCC | 3.57e-02 | 2.16e-02 | 0.0662 |
| 253832 | ZDHHC20 | LZE24T | Human | Esophagus | ESCC | 8.26e-11 | 7.63e-02 | 0.0596 |
| 253832 | ZDHHC20 | P2T-E | Human | Esophagus | ESCC | 2.83e-15 | 2.85e-01 | 0.1177 |
| 253832 | ZDHHC20 | P4T-E | Human | Esophagus | ESCC | 8.21e-10 | 2.15e-01 | 0.1323 |
| 253832 | ZDHHC20 | P5T-E | Human | Esophagus | ESCC | 3.86e-08 | 4.18e-02 | 0.1327 |
| 253832 | ZDHHC20 | P8T-E | Human | Esophagus | ESCC | 1.69e-12 | 2.15e-01 | 0.0889 |
| 253832 | ZDHHC20 | P10T-E | Human | Esophagus | ESCC | 6.94e-17 | 3.88e-01 | 0.116 |
| 253832 | ZDHHC20 | P11T-E | Human | Esophagus | ESCC | 6.20e-04 | 1.23e-01 | 0.1426 |
| 253832 | ZDHHC20 | P12T-E | Human | Esophagus | ESCC | 1.96e-09 | 6.39e-02 | 0.1122 |
| 253832 | ZDHHC20 | P15T-E | Human | Esophagus | ESCC | 1.56e-15 | 2.87e-01 | 0.1149 |
| 253832 | ZDHHC20 | P16T-E | Human | Esophagus | ESCC | 7.09e-22 | 6.20e-01 | 0.1153 |
| 253832 | ZDHHC20 | P20T-E | Human | Esophagus | ESCC | 9.32e-05 | 1.37e-01 | 0.1124 |
| 253832 | ZDHHC20 | P21T-E | Human | Esophagus | ESCC | 1.02e-08 | 1.70e-01 | 0.1617 |
| 253832 | ZDHHC20 | P22T-E | Human | Esophagus | ESCC | 2.75e-15 | 1.41e-01 | 0.1236 |
| 253832 | ZDHHC20 | P23T-E | Human | Esophagus | ESCC | 7.89e-06 | 1.20e-01 | 0.108 |
| 253832 | ZDHHC20 | P24T-E | Human | Esophagus | ESCC | 9.80e-14 | 1.02e-01 | 0.1287 |
| 253832 | ZDHHC20 | P26T-E | Human | Esophagus | ESCC | 1.54e-12 | 7.46e-02 | 0.1276 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000660510 | Cervix | CC | protein targeting | 68/2311 | 314/18723 | 2.17e-06 | 6.55e-05 | 68 |
| GO:00901509 | Cervix | CC | establishment of protein localization to membrane | 54/2311 | 260/18723 | 7.67e-05 | 1.05e-03 | 54 |
| GO:0006605111 | Esophagus | ESCC | protein targeting | 229/8552 | 314/18723 | 4.93e-23 | 1.01e-20 | 229 |
| GO:0090150110 | Esophagus | ESCC | establishment of protein localization to membrane | 182/8552 | 260/18723 | 1.27e-15 | 8.19e-14 | 182 |
| GO:004354313 | Esophagus | ESCC | protein acylation | 165/8552 | 243/18723 | 1.69e-12 | 7.14e-11 | 165 |
| GO:00421573 | Esophagus | ESCC | lipoprotein metabolic process | 86/8552 | 135/18723 | 1.78e-05 | 1.57e-04 | 86 |
| GO:00064973 | Esophagus | ESCC | protein lipidation | 62/8552 | 92/18723 | 2.08e-05 | 1.80e-04 | 62 |
| GO:00421583 | Esophagus | ESCC | lipoprotein biosynthetic process | 64/8552 | 96/18723 | 2.61e-05 | 2.20e-04 | 64 |
| GO:00066124 | Esophagus | ESCC | protein targeting to membrane | 83/8552 | 131/18723 | 3.31e-05 | 2.73e-04 | 83 |
| GO:0043543 | Liver | NAFLD | protein acylation | 43/1882 | 243/18723 | 1.70e-04 | 3.07e-03 | 43 |
| GO:00066057 | Liver | Cirrhotic | protein targeting | 148/4634 | 314/18723 | 3.86e-18 | 6.20e-16 | 148 |
| GO:00901507 | Liver | Cirrhotic | establishment of protein localization to membrane | 123/4634 | 260/18723 | 1.85e-15 | 2.15e-13 | 123 |
| GO:00435431 | Liver | Cirrhotic | protein acylation | 95/4634 | 243/18723 | 4.73e-07 | 1.07e-05 | 95 |
| GO:00066122 | Liver | Cirrhotic | protein targeting to membrane | 53/4634 | 131/18723 | 5.17e-05 | 5.95e-04 | 53 |
| GO:0042157 | Liver | Cirrhotic | lipoprotein metabolic process | 53/4634 | 135/18723 | 1.32e-04 | 1.29e-03 | 53 |
| GO:0042158 | Liver | Cirrhotic | lipoprotein biosynthetic process | 36/4634 | 96/18723 | 3.69e-03 | 2.03e-02 | 36 |
| GO:0006497 | Liver | Cirrhotic | protein lipidation | 33/4634 | 92/18723 | 1.12e-02 | 4.92e-02 | 33 |
| GO:000660512 | Liver | HCC | protein targeting | 219/7958 | 314/18723 | 7.74e-23 | 1.49e-20 | 219 |
| GO:009015012 | Liver | HCC | establishment of protein localization to membrane | 168/7958 | 260/18723 | 4.07e-13 | 2.13e-11 | 168 |
| GO:00435432 | Liver | HCC | protein acylation | 157/7958 | 243/18723 | 2.40e-12 | 1.12e-10 | 157 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZDHHC20 | SNV | Missense_Mutation | c.904N>A | p.Glu302Lys | p.E302K | Q5W0Z9 | protein_coding | deleterious(0.01) | possibly_damaging(0.804) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ZDHHC20 | SNV | Missense_Mutation | rs748009023 | c.718A>G | p.Thr240Ala | p.T240A | Q5W0Z9 | protein_coding | deleterious(0) | possibly_damaging(0.765) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ZDHHC20 | SNV | Missense_Mutation | c.316N>C | p.Ile106Leu | p.I106L | Q5W0Z9 | protein_coding | deleterious(0.02) | probably_damaging(0.914) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| ZDHHC20 | SNV | Missense_Mutation | novel | c.763N>A | p.Asp255Asn | p.D255N | Q5W0Z9 | protein_coding | deleterious(0) | possibly_damaging(0.884) | TCGA-VS-A8Q8-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| ZDHHC20 | SNV | Missense_Mutation | c.818N>G | p.Asp273Gly | p.D273G | Q5W0Z9 | protein_coding | deleterious(0) | probably_damaging(0.929) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ZDHHC20 | SNV | Missense_Mutation | c.834G>T | p.Trp278Cys | p.W278C | Q5W0Z9 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-3496-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ZDHHC20 | SNV | Missense_Mutation | novel | c.273N>T | p.Lys91Asn | p.K91N | Q5W0Z9 | protein_coding | deleterious(0.03) | possibly_damaging(0.805) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ZDHHC20 | SNV | Missense_Mutation | c.22N>T | p.Arg8Cys | p.R8C | Q5W0Z9 | protein_coding | deleterious(0) | possibly_damaging(0.855) | TCGA-AA-A01P-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
| ZDHHC20 | SNV | Missense_Mutation | c.757N>A | p.Gly253Arg | p.G253R | Q5W0Z9 | protein_coding | deleterious(0.03) | probably_damaging(0.998) | TCGA-AA-A01R-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5-fluorouracil | PD | |
| ZDHHC20 | SNV | Missense_Mutation | c.1014A>C | p.Glu338Asp | p.E338D | Q5W0Z9 | protein_coding | tolerated(0.34) | benign(0) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |